{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:27:00Z","timestamp":1792783620637,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Australian Government Research Training Program (RTP) Fee Offset Scholarship through Federation University Australia","id":[{"id":"https:\/\/ror.org\/0314h5y94","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006643","name":"Federation University Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006643","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to systematically assess the efficacy of cardioprotective agents in preventing anthracycline-induced cardiotoxicity in patients with breast cancer using a comprehensive network meta-analysis (NMA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included patients with breast cancer undergoing anthracycline-based chemotherapy. Randomized controlled trials (RCTs) published before March 2020 were identified through systematic searches in MEDLINE, Cochrane CENTRAL, Web of Science, and CINAHL. The primary outcome was left ventricular ejection fraction (LVEF), assessed using cardiac magnetic resonance imaging, multigated radionuclide angiography, or echocardiography. The NMA integrated direct and indirect comparisons to estimate the relative effectiveness of pharmacological interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The systematic review included 31 RCTs with 3,228 participants, whereas the NMA synthesized 25 effect sizes from 15 RCTs. Mineralocorticoid receptor antagonists (MRAs) [standardized mean difference (SMD): \u22121.78, 95% confidence interval (CI): \u22122.81 to \u22120.75] and trimetazidine (SMD: \u22121.12, 95%CI: \u22122.32 to \u22120.09) exhibited the most substantial cardioprotective effects. Dexrazoxane (SMD: \u22120.53, 95%CI: \u22121.90 to \u22120.02) and \u03b2-blockers (SMD: \u22120.34, 95%CI: \u22120.70 to 0.02) showed potential benefits, albeit with greater uncertainty. Direct comparisons showed that dexrazoxane was more effective than \u03b2-blockers (SMD: \u22121.25, 95%CI: \u22122.22 to \u22120.48), with mineralocorticoid receptor antagonists (MRAs) outperforming both. Despite heterogeneity and potential publication bias, mineralocorticoid receptor antagonists (MRAs) and trimetazidine consistently ranked as the most effective interventions. LVEF findings confirmed the cardioprotective benefits of \u03b2-blockers, ARBs, ACE inhibitors, and dexrazoxane.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RCT evidence suggested that cardioprotective drugs effectively mitigate anthracycline-induced LVEF decline. However, the lack of direct head-to-head trials limits definitive conclusions on comparative efficacy, warranting trials in patients with lower baseline LVEF to optimize cardioprotective strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-025-07791-7","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T07:54:39Z","timestamp":1754380479000},"page":"1-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacological interventions for anthracycline-induced cardiotoxicity in breast cancer: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8290-0325","authenticated-orcid":false,"given":"Pinyadapat","family":"Vacharanukrauh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh M.","family":"Alif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergal","family":"Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Aziz","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"issue":"10","key":"7791_CR1","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, ESC Scientific Document Group (2022) 2022 ESC guidelines on cardio-oncology developed in collaboration with the european hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS). Eur Heart J Cardiovasc Imaging 23(10):e333\u2013e465. https:\/\/doi.org\/10.1093\/ehjci\/jeac106","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"36","key":"7791_CR2","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, ESC Scientific Document Group (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768\u20132801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"issue":"10","key":"7791_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalh\u00e3es A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 15(10):1063\u20131093. https:\/\/doi.org\/10.1093\/ehjci\/jeu192","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"7791_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2020) Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 31(2):171\u2013190. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.023","journal-title":"Ann Oncol"},{"issue":"3","key":"7791_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10741-018-9755-3","volume":"24","author":"S Huang","year":"2019","unstructured":"Huang S, Zhao Q, Yang Z-G, Diao K-Y, He Y, Shi K, Shen M-T, Fu H, Guo Y-K (2019) Protective role of beta-blockers in chemotherapy-induced cardiotoxicity\u2014A systematic review and meta-analysis of carvedilol. Heart Fail Rev 24(3):325\u2013333. https:\/\/doi.org\/10.1007\/s10741-018-9755-3","journal-title":"Heart Fail Rev"},{"issue":"8","key":"7791_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand J-B, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol 35(8):893\u2013911. https:\/\/doi.org\/10.1200\/JCO.2016.70.5400","journal-title":"J Clin Oncol"},{"issue":"13","key":"7791_CR7","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","volume":"49","author":"K Kalam","year":"2013","unstructured":"Kalam K, Marwick TH (2013) Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 49(13):2900\u20132909. https:\/\/doi.org\/10.1016\/j.ejca.2013.04.030","journal-title":"Eur J Cancer"},{"key":"7791_CR8","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3389\/fphar.2018.01262","volume":"9","author":"CG Nebigil","year":"2018","unstructured":"Nebigil CG, D\u00e9saubry LJF (2018) Updates in anthracycline-mediated cardiotoxicity. Front Pharmacol 9:1262. https:\/\/doi.org\/10.3389\/fphar.2018.01262","journal-title":"Front Pharmacol"},{"issue":"6","key":"7791_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.medcli.2016.02.025","volume":"147","author":"B Hutton","year":"2016","unstructured":"Hutton B, Catal\u00e1-L\u00f3pez F, Moher DJMC (2016) The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA. Med Clin (Barc) 147(6):262\u2013266. https:\/\/doi.org\/10.1016\/j.medcli.2016.02.025","journal-title":"Med Clin (Barc)"},{"key":"7791_CR10","doi-asserted-by":"crossref","unstructured":"Jansen JP, Naci HJB m (2013) Is network meta-analysis as valid as standard pairwise meta-analysis? It All Depends Distrib Eff Mod 11(1):1\u20138","DOI":"10.1186\/1741-7015-11-159"},{"key":"7791_CR11","unstructured":"StataCorp, L (2017) Stata statistical software, release 15. College Station, TX"},{"issue":"7","key":"7791_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JPT (2014) Evaluating the quality of evidence from a network meta-analysis. PLoS ONE 9(7):e99682. https:\/\/doi.org\/10.1371\/journal.pone.0099682","journal-title":"PLoS ONE"},{"issue":"1","key":"7791_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.196","volume":"17","author":"M Akpek","year":"2015","unstructured":"Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, Berk V, Karaca H, Kalay N, Oguzhan A, Ergin A (2015) Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 17(1):81\u201389. https:\/\/doi.org\/10.1002\/ejhf.196","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"7791_CR14","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","volume":"71","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F, Goncalves Brandao SM, Rigaud VO, Higuchi-dos-Santos MH, Hajjar LA, Kalil Filho R, Hoff PM, Sahade M (2018) Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 71(20):2281\u20132290","journal-title":"J Am Coll Cardiol"},{"key":"7791_CR15","doi-asserted-by":"publisher","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, Jr., das Dores Cruz F, Gon\u00e7alves Brand\u00e3o SM, Rigaud VOC, Higuchi-Dos-Santos MH, Hajjar LA, Kalil Filho R, Hoff PM, Sahade M, Ferrari MSM, de Paula Costa RL, Mano MS, Bittencourt Viana Cruz CB, Abduch MC, Lofrano Alves MS, Guimaraes GV, Issa VS, Bittencourt MS, Bocchi EA (2018) Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial. J Am Coll Cardiol 71(20):2281\u20132290. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.049","DOI":"10.1016\/j.jacc.2018.02.049"},{"key":"7791_CR16","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.2147\/CMAR.S166481","volume":"10","author":"F Cochera","year":"2018","unstructured":"Cochera F, Dinca D, Bordejevic DA, Citu IM, Mavrea AM, Andor M, Trofenciuc M, Tomescu MCJC (2018) Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer. Cancer Manag Res 10:2071\u20132081. https:\/\/doi.org\/10.2147\/CMAR.S166481","journal-title":"Cancer Manag Res"},{"issue":"2","key":"7791_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaccao.2019.10.001","volume":"1","author":"MK Davis","year":"2019","unstructured":"Davis MK, Villa D, Tsang TSM, Starovoytov A, Gelmon K, Virani SA (2019) Effect of eplerenone on diastolic function in women receiving anthracycline-based chemotherapy for breast cancer. JACC CardioOncol 1(2):295\u2013298. https:\/\/doi.org\/10.1016\/j.jaccao.2019.10.001","journal-title":"JACC CardioOncol"},{"issue":"5","key":"7791_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","volume":"21","author":"A Elitok","year":"2014","unstructured":"Elitok A, Oz F, Cizgici AY, Kilic L, Ciftci R, Sen F, Bugra Z, Mercanoglu F, Oncul A, Oflaz HJC (2014) Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up. Cardiol J 21(5):509\u2013515. https:\/\/doi.org\/10.5603\/CJ.a2013.0150","journal-title":"Cardiol J"},{"issue":"21","key":"7791_CR19","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland \u00c5, Stor\u00e5s TH, Hagve T-A, R\u00f8sj\u00f8 H, Steine K, Geisler J, Omland T (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37(21):1671\u20131680. https:\/\/doi.org\/10.1093\/eurheartj\/ehw022","journal-title":"Eur Heart J"},{"issue":"11","key":"7791_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006513","volume":"6","author":"G Gulati","year":"2017","unstructured":"Gulati G, Heck SL, R\u00f8sj\u00f8 H, Ree AH, Hoffmann P, Hagve T-A, Norseth J, Gravdehaug B, Steine K, Geisler J, Omland T (2017) Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (prevention of cardiac dysfunction during adjuvant breast cancer therapy) study. J Am Heart Assoc 6(11):e006513. https:\/\/doi.org\/10.1161\/JAHA.117.006513","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"7791_CR21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/ehjci\/jex159","volume":"19","author":"SL Heck","year":"2018","unstructured":"Heck SL, Gulati G, Hoffmann P, von Knobelsdorff-Brenkenhoff F, Stor\u00e5s TH, Ree AH, Gravdehaug B, R\u00f8sj\u00f8 H, Steine K, Geisler J, Schulz-Menger J, Omland T (2018) Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial. Eur Heart J Cardiovasc Imaging 19(5):544\u2013552. https:\/\/doi.org\/10.1093\/ehjci\/jex159","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"5","key":"7791_CR22","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/J.IJCARD.2012.06.023","volume":"167","author":"MG Kaya","year":"2013","unstructured":"Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, Kalay N, Dikilitas M, Yarlioglues M, Karaca H, Berk V, Ardic I, Ergin A, Lam YY (2013) Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 167(5):2306\u20132310. https:\/\/doi.org\/10.1016\/J.IJCARD.2012.06.023","journal-title":"Int J Cardiol"},{"issue":"12","key":"7791_CR23","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1002\/cam4.3956","volume":"10","author":"M Lee","year":"2021","unstructured":"Lee M, Chung WB, Lee JE, Park CS, Park WC, Song BJ, Youn HJ (2021) Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. Cancer Med 10(12):3964\u20133973. https:\/\/doi.org\/10.1002\/cam4.3956","journal-title":"Cancer Med"},{"issue":"4","key":"7791_CR24","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/annonc\/mdj134","volume":"17","author":"M Marty","year":"2006","unstructured":"Marty M, Espie M, Llombart A, Monnier A, Rapoport B, Stahalova V, Oncology (2006) Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane\u00ae) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol 17(4):614\u2013622","journal-title":"Ann Oncol"},{"issue":"1","key":"7791_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a058356","volume":"4","author":"K Mross","year":"1993","unstructured":"Mross K, Bohn C, Edler L, Jonat W, Queisser W, Heidemann E, Goebel M, Hossfeld DK (1993) Randomized phase II study of single-agent epirubicin +\/\u2212 verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German cancer society. Ann Oncol 4(1):45\u201350. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a058356","journal-title":"Ann Oncol"},{"issue":"5","key":"7791_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","volume":"69","author":"M Nabati","year":"2017","unstructured":"Nabati M, Janbabai G, Baghyari S, Esmaili K, Yazdani J (2017) Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol 69(5):279\u2013285. https:\/\/doi.org\/10.1097\/FJC.0000000000000470","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"7791_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.33963\/KP.15163","volume":"78","author":"AJ S\u0142owik","year":"2020","unstructured":"S\u0142owik AJ, Jagielski P, Potocki P, Streb J, Ochenduszko S, Wysocki P, Gajos G, Konduracka E (2020) Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: Results of a prospective randomized study. Polish Heart J 78(2):131\u2013137. https:\/\/doi.org\/10.33963\/KP.15163","journal-title":"Polish Heart J"},{"issue":"12","key":"7791_CR28","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJM198809223191203","volume":"319","author":"JL Speyer","year":"1988","unstructured":"Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319(12):745\u2013752. https:\/\/doi.org\/10.1056\/NEJM198809223191203","journal-title":"N Engl J Med"},{"issue":"2\u20133","key":"7791_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0305-7372(90)90041-d","volume":"17","author":"JL Speyer","year":"1990","unstructured":"Speyer JL, Green MD, Sanger J, Zeleniuch-Jacquotte A, Kramer E, Rey M, Wernz JC, Blum RH, Hochester H, Meyers M (1990) A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer Treat Rev 17(2\u20133):161\u2013163. https:\/\/doi.org\/10.1016\/0305-7372(90)90041-d","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"7791_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/JCO.1992.10.1.117","volume":"10","author":"JL Speyer","year":"1992","unstructured":"Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10(1):117\u2013127. https:\/\/doi.org\/10.1200\/JCO.1992.10.1.117","journal-title":"J Clin Oncol"},{"issue":"5","key":"7791_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/MAJ.0000000000000432","volume":"349","author":"F Sun","year":"2015","unstructured":"Sun F, Qi X, Geng C, Li X (2015) Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity [Journal Article; Randomized Controlled Trial]. Am J Med Sci 349(5):406\u2013412. https:\/\/doi.org\/10.1097\/MAJ.0000000000000432","journal-title":"Am J Med Sci"},{"issue":"44","key":"7791_CR32","doi-asserted-by":"publisher","first-page":"e5228","DOI":"10.1097\/MD.0000000000005228","volume":"95","author":"F Sun","year":"2016","unstructured":"Sun F, Shi J, Geng C (2016) Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes. Medicine 95(44):e5228. https:\/\/doi.org\/10.1097\/MD.0000000000005228","journal-title":"Medicine"},{"issue":"4","key":"7791_CR33","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","volume":"15","author":"SM Swain","year":"1997","unstructured":"Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15(4):1333\u20131340. https:\/\/doi.org\/10.1200\/JCO.1997.15.4.1333","journal-title":"J Clin Oncol"},{"issue":"4","key":"7791_CR34","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","volume":"15","author":"SM Swain","year":"1997","unstructured":"Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15(4):1318\u20131332. https:\/\/doi.org\/10.1200\/JCO.1997.15.4.1318","journal-title":"J Clin Oncol"},{"issue":"2","key":"7791_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/000331970305400212","volume":"54","author":"D Tallarico","year":"2003","unstructured":"Tallarico D, Rizzo V, Di Maio F, Petretto F, Bianco G, Placanica G, Marziali M, Paravati V, Gueli N, Meloni F, Campbell SV (2003) Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. Angiology 54(2):219\u2013227. https:\/\/doi.org\/10.1177\/000331970305400212","journal-title":"Angiology"},{"issue":"1","key":"7791_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000442722","volume":"134","author":"A Tashakori Beheshti","year":"2016","unstructured":"Tashakori Beheshti A, Mostafavi Toroghi H, Hosseini G, Zarifian A, Homaei Shandiz F, Fazlinezhad A (2016) Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial. Cardiology 134(1):47\u201353. https:\/\/doi.org\/10.1159\/000442722","journal-title":"Cardiology"},{"issue":"12","key":"7791_CR37","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1200\/JCO.1996.14.12.3112","volume":"14","author":"M Venturini","year":"1996","unstructured":"Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, Cyrus P, Vinke J, Testore F, Guelfi M, Lionetto R, Bruzzi P, Conte PF, Rosso R (1996) Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14(12):3112\u20133120. https:\/\/doi.org\/10.1200\/JCO.1996.14.12.3112","journal-title":"J Clin Oncol"},{"issue":"921","key":"7791_CR38","first-page":"15","volume":"149","author":"P Vici","year":"1998","unstructured":"Vici P, Ferraironi A, Di Lauro L, Carpano S, Conti F, Belli F, Paoletti G, Maini CL, Lopez M (1998) Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment. Clin Ter 149(921):15\u201320","journal-title":"Clin Ter"},{"issue":"7","key":"7791_CR39","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.cjca.2016.02.078","volume":"32","author":"SA Virani","year":"2016","unstructured":"Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, Johnson C, Lemieux J, Paterson I, Sebag IA, Simmons C, Sulpher J, Thain K, Thavendiranathan P, Wentzell JR, Wurtele N, C\u00f4t\u00e9 MA, Fine NM, Haddad H, Hayley BD, Hopkins S, Joy AA, Rayson D, Stadnick E, Straatman L (2016) Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol 32(7):831\u2013841. https:\/\/doi.org\/10.1016\/j.cjca.2016.02.078","journal-title":"Can J Cardiol"},{"key":"7791_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM (2020) Cardiotoxicity of anthracyclines. Front Cardiovasc Med 7:26. https:\/\/doi.org\/10.3389\/fcvm.2020.00026","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"7791_CR41","first-page":"936","volume":"35","author":"L Liu","year":"2013","unstructured":"Liu L, Liu ZZ, Liu YY, Zheng ZD, Liang XF, Han YL, Xie XD (2013) Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer. Zhonghua Zhong Liu Za Zhi [Zhonghua Zhong Liu Za Zhi] 35(12):936\u2013940","journal-title":"Zhonghua Zhong Liu Za Zhi [Zhonghua Zhong Liu Za Zhi]"},{"issue":"3","key":"7791_CR42","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/annonc\/mdw671","volume":"28","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, Ong G, Fazelzad R, Amir E, Lee DS, Thavendiranathan P, Tomlinson G (2017) Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis. Ann Oncol 28(3):628\u2013633. https:\/\/doi.org\/10.1093\/annonc\/mdw671","journal-title":"Ann Oncol"},{"key":"7791_CR43","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","volume":"94","author":"D Cardinale","year":"2018","unstructured":"Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, Cucchi G, Menatti E, Mangiavacchi M, Cavina R et al (2018) Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer 94:126\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.005","journal-title":"Eur J Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07791-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07791-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07791-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:47:38Z","timestamp":1757350058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07791-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7791"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07791-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study is a systematic review and meta-analysis and did not involve human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}